<SEC-DOCUMENT>0001104659-20-085602.txt : 20200722
<SEC-HEADER>0001104659-20-085602.hdr.sgml : 20200722
<ACCEPTANCE-DATETIME>20200722160020
ACCESSION NUMBER:		0001104659-20-085602
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200722
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200722
DATE AS OF CHANGE:		20200722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		201041519

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2025401d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
<B>WASHINGTON, D. C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 18%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
July 22, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRECIPIO, INC.<BR>
</B><I>(Exact Name of Registrant as Specified in Its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Delaware<BR>
</B><I>(State of Incorporation)</I></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>001-36439<BR>
</B><I>(Commission File Number)</I></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>91-1789357<BR>
</B><I>(I.R.S. Employer Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4 Science Park, New Haven, CT 06511</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive offices)
(Zip Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(203) 787-7888</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Registrant's telephone number, including
area code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 18%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable<BR>
</B><I>(Former name, former address and former fiscal year, if changed since last report date)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 18%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding: 1.5pt; font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center; width: 33%">Title of each class</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center; width: 34%">Ticker symbol(s)</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center; width: 33%">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">Common Stock, $0.01 par value per share</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">PRPO</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">The Nasdaq Stock Market LLC</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">Emerging growth company <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt"></P>





<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
2.02 Results of Operations and financial Conditions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On July 22, 2020,
the Company issued a press release announcing its preliminary, unaudited Pathology Services Revenue for the Q2-2020. The press
release is furnished as Exhibit 99.1 and incorporated herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Current Report on Form 8-K, including
Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that
Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated
by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before
or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby
shall not be deemed an admission as to the materiality of any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.55in; text-align: left"><A HREF="tm2025401d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="text-align: justify"><A HREF="tm2025401d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Precipio Inc Press Release July 22, 2020</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>PRECIPIO, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 47%">s/ Ilan Danieli </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Ilan Danieli</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&#9;July 22, 2020 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2025401d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Precipio Announces Q2-2020 Unaudited
Pathology Services Revenue Increased Approximately 50% over Q1&rsquo;20</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEW HAVEN, CT, (July 22, 2020) &ndash;
</B>Specialty diagnostics company <FONT STYLE="color: #1155CC"><U>Precipio, Inc</U>.</FONT> (<FONT STYLE="color: #1155CC"><U>NASDAQ:
PRPO</U></FONT>), announced its preliminary unaudited revenues for its pathology services increased from $0.8M in Q1&rsquo;20,
to an estimated (unaudited) $1.3M in Q2&rsquo;20, an increase of approximately 50% quarter-over-quarter. Final numbers are subject
to the completion of the company&rsquo;s quarterly review and will be released in the company&rsquo;s upcoming 10-Q filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A detailed analysis on the metrics driving
growth in pathology services will be shared following the release of the company&rsquo;s second quarter financials. Early indications
point to sustained volume increases from the company&rsquo;s existing customer base, coupled with our successful March transition
of all the Oncometrix accounts. For reference, in May 2020 Precipio reported a 27% increase in pathology services in Q1&rsquo;20
over Q4&rsquo;19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our growth of pathology
revenues, we are very encouraged by the reception of our HemeScreen Reagent Rental (&ldquo;HSRR&rdquo;) offering by office-based
oncology practices. As announced in May 2020, we launched the HSRR program to create a new revenue opportunity for oncology practices
to run molecular tests of various hematologic malignancies in their office laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As first reported in 2019, HemeScreen is
a proprietary technology developed by Precipio that substantially reduces the costs for running molecular tests for hematologic
malignancies. The first assay for MPN malignancies tests for JAK2, MPL and CALR genes. In addition to the significant cost reduction,
HemeScreen also lowers the volume threshold enabling the office-based oncologist laboratory to generate results in a 2-day turn-around
on most cases vs the current 14-28 day turn-around time for most labs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With HSRR, Precipio has harnessed the intrinsic
values of its proprietary HemeScreen technology (reduced costs and diagnostic speed) creating a compelling economic model for oncologist
practices. As the states are gradually opening up for business, we are very pleased by the enthusiastic reception of HSRR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;While many companies and businesses
have been ravaged by the COVID-19 pandemic, we are grateful for our customers who continue to place their trust in our services,&rdquo;
said Ilan Danieli, Precipio&rsquo;s CEO. &ldquo;The ability to grow our business during what is likely the greatest economic downturn
in world history, is a testament to the value of what we do, and the resilience of our business&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222"><B>About
Precipio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Precipio has
built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed
within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through
its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the
Yale School of Medicine and Harvard&rsquo;s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy
enabling the highest level of patient care. For more information, please visit <FONT STYLE="color: Blue"><U>www.precipiodx.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222"><B>Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">This
press release contains &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to
the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers,
and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether
concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information,
statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per
share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management&rsquo;s
estimates, beliefs, assumptions and projections. Words such as &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
 &ldquo;will,&rdquo; &ldquo;targets,&rdquo; &ldquo;goals,&rdquo; &ldquo;projects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
 &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; and variations on such words, and
similar expressions that reflect our current views with respect to future events and operational, economic and financial performance,
are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks
and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance
and cause results to differ materially from management&rsquo;s expectations, or could affect the company&rsquo;s ability to achieve
its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company&rsquo;s business, operations and
employees and the other factors that are described in the sections entitled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis&rdquo; in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated
from time to time in the company&rsquo;s Securities and Exchange Commission filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">The
company&rsquo;s forward-looking statements in this press release are based on management&rsquo;s current views, beliefs, assumptions
and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222"><B>Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #1155CC"><B><U>investors@precipiodx.com</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #1155CC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">+1-203-787-7888
Ext. 523</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( 6\# 2(  A$! Q$!_\0
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ML],^@^M<\FL?$C6AYUAHECI=NW*_;&RY'N.OZ5H>"/!@TQ/[:UG_ $K7KO\
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M[G4%U>6]C;O<74\<$*#+22,%5?J34PKB_BN,_#S43Z-$?_'Q7'%7:1U,V_\
MA,/#?_0=T[_P(7_&C_A+_#G_ $'=._\  A?\:P](^'WA.YT6PGFT2W>62WC=
MV);DE02>M7?^%;^$/^@%;_\ ?3?XU7N>8:EN;QIX9@B:1]=L-H&3MF#'\AR:
MXAKN7XG>++'['#(GAS2Y?.>>1=OGR#H!_AZ9SU%=:GPZ\(QN'70K7(Z;MS#\
MB:Z.WMH;6!(8(HXHD&%2-0JJ/8"CFC'X=PLV++-';Q-+,ZI&@+,[' 4#J2:R
M?^$O\-_]!W3O_ A?\:C\:@'P1K0/_/G)_*N5\$^!O#6J>#-+O;W2()KF:'=)
M(Q;+')]#2C&-KL&W<Z[_ (2_PW_T'=._\"%_QIK>,O#2*6;7=/P.3BX4_P!:
MI?\ "M_"'_0"M_\ OIO\:YWQ1HG@SPFVG37'A>*2UN;CR99P[;8/0D9Y^GL:
MI*#=M0U*>O:PWQ+U.#P[H:R-I,4RR7U\5(4@= ,_IZG'85Z9<Q+#I,\2*%1(
M&50.P"X%+8V5G8VJ06,$,%N.52%0J_7BG7__ "#KK_KD_P#(TG*]DM@L<'\+
M+ZUT[X:Q75[<1V]ND\FZ21@JCYO4UT__  FGAC_H/Z=_X$+_ (URWPQTVSU?
MX9165_;QW%L\\FZ.09!PV1^M;_\ PKOPC_T ;7\C_C53Y>=W$KV+7_":>&/^
M@]IW_@0O^-:EEJ%IJ5LMS97,5Q V=LD3!E..O(K!_P"%=^$?^@#:_D?\:V],
MTJQT>R6ST^VCMK=22(XQ@9/4U#Y>@]2Y7G/BA/[7^*_AG2I>;>VB>\9#T+#)
M'_H(KT:O.O$CC2_BYX:U*08@NH7M"QZ!N0/_ $):=/?[P9Z*!BBBBH&%%%%
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MSQ-2>ES14XH[95"J !@#H*6BBL"PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N?UFTC74X+^X2=K81&&4P2.ICYR&(4@D=0?3@T44)B9-I]WH<
M4WEV6I0R32X 1KPR,3Z ,QJ"'38]=NCJ=UY@56:.W2)S&0@)&69<$Y()QG ^
MM%%4U8E.X6]F-!O!;6^YK6\WD;SN=)0I;[QY8$ ]<XQ3]+T>UN='LYIGNVDD
M@1G)NY>25&?XJ**'M<JPS4X]/L;O3()FCMK,),@^?RP.%X!&,5-97F@VTI%K
MJ$1>3"X:Z+Y]  2:**I0O&Y+=F)'=1Z->W<=Z?)MYY3/%<-]SD#<K'^$@COU
M!]JT;75=/O93%:7UM/(!N*Q2JQ ]< T45-O=N.^MB#5!F[TO_K[_ /:;UI"B
MBI*,O6?OZ;_U^Q_R:K'V1CK O=PVB P[<<YW Y_2BBCH!CE)5N+J\AB:5K74
M2[1K]YD,2JV!W(!SCOC%7V\1:9Y9\NY6:4_=MXAF4GTV=0?KBBBK2YKW);L9
MMEICRZBL-_YH)MVG:..9U57>5B1\I&< @?A4T=I#8:A?0^42TMN7@E9F=MH&
M&3+$]#@^^?:BBI&5;&;P\^GVCSWZ+-Y$>\?;&7!"@= V!70)J5B]K]I2ZB:#
0=M\Q6R,^F:**TE"S)4C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
